compounded semaglutide news compounding fda FDA moves to stop compounding GLP-1 drugs versions of weight loss – compounding semaglutide news FDA alerts

These compounds dont completely block the enzyme but may slow activity enough to extend GLP-1s active window from 2-3 minutes to 4-6 minutesa doubling of half-life that can significantly enhance metabolic coordination

Primary completion expected August 2030 (full study completion ~August 2032)

It typically includes information such as product identity, purity, and testing methodology

Usage is restricted to certified laboratories

Read the full article to see what a more sustainable approach looks like: Marsh McLennan Agency #ObesityCare #WeightManagement #WorkplaceWellbeing Why obesity care strategies must go beyond GLP1s to drive sustainable outcomes To view or add a comment, sign in A very special thanks to my friend Betsy Nota-Kirby for her partnership, and for dropping some of her vast knowledge on GLP-1 strategies within this HR Dive article